Why the study?
What are the safety, long-term outcomes, and predictors of recurrence after first-line combined endoepicardial ventricular tachycardia substrate ablation in arrhythmogenic cardiomyopathy?
What are the safety, long-term outcomes, and predictors of recurrence after first-line combined endoepicardial ventricular tachycardia substrate ablation in arrhythmogenic cardiomyopathy?
First-line combined endoepicardial VT ablation is effective in arrhythmogenic cardiomyopathy, though left-dominant disease carries a higher recurrence risk and the Bi/Uni-LVA ratio can guide the need for an epicardial approach.
May support first-line endoepicardial VT ablation in AC; leaves open optimal strategies for left-dominant forms pending randomized data.
First-line endoepicardial VT substrate ablation achieves good long-term results in AC. Left-dominant AC is associated with an increased risk of recurrence. The Bi/Uni-LVA ratio identifies patients with limited epicardial arrhythmogenic substrate in whom the indication of epicardial approach should be more cautiously assessed.
No takes yet. Share an insight, caveat, or question.
Berruezo et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: